menu search

Eli lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%

Eli Lilly's stock has been on a tear, driven by positive trial results for its Alzheimer's drug and progress with its promising ...

August 8, 2023, 7:04 am

Novo nordisk says wegovy reduced risk of adverse cardiovascular events by 20% in adults with obesity in trial

Novo Nordisk's U.S.-listed stock NVO, +3.04% NOVO.B, +10.32% rose 10% premarket Tuesday, after the company said its ...

August 8, 2023, 6:19 am

Rhythm pharmaceuticals: a virtual monopoly in orphan obesity disorders

Rhythm Pharmaceuticals, Inc. is focused on developing treatments for orphan obesity syndromes caused by...

August 4, 2023, 3:08 pm

Terns pharmaceuticals announces leadership transition

Senthil Sundaram Stepping Down as Chief Executive Officer for Health Reasons FOSTER CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuti...

August 3, 2023, 9:05 pm

The issue with eli lilly is the very competitive drug market, says short hills partners' weiss

CNBC's 'Halftime Report' Investment Committee discusses Eli Lilly's current valuation relative to revenue growth, and the ...

August 2, 2023, 2:17 pm

Eli lilly: there is no logic to this over optimism

Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV's Humira. This naturally explains Mr. Market's optimism surrounding the LLY's st...

July 28, 2023, 4:00 pm

Eli lilly vs. novo nordisk: what's the better weight-loss stock to buy?

Eli Lilly has a couple of promising weight-loss treatments that could gain approval in the near future. Novo Nordisk's ...

July 27, 2023, 8:15 am

Intuitive surgical stock slips on slowing growth of bariatric surgeries during 2q

Intuitive Surgical (NASDAQ:ISRG) shares slipped on weaker demand for bariatric surgeries during the second quarter despite outperforming the Street's ...

July 21, 2023, 10:27 am

Weightwatchers bets on trendy obesity drugs

For decades, WeightWatchers taught dieters there was only one way to shed the pounds: hard-won behavioral change. Now, the company is taking a sharp t...

July 19, 2023, 4:47 pm

Rhythm pharmaceuticals to report second quarter 2023 financial results on tuesday, august 1, 2023

BOSTON, July 18, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transf...

July 15, 2023, 6:29 am

Rhythm pharmaceuticals to report second quarter 2023 financial results on tuesday, august 1, 2023

BOSTON, July 18, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transf...

July 15, 2023, 2:12 am

Eli lilly buys versanis to boost its obesity drug portfolio

Eli Lilly agreed to buy biopharma firm Versanis for up to $1.93 billion, boosting Lilly's reach into the obesi...

July 14, 2023, 4:55 pm

Eli lilly to expand in obesity drugs with $1.925 billion acquisition of versanis bio

Shares of Eli Lilly & Co (NYSE: LLY) gained nearly 4.0% today after the pharmaceutical behemoth said it will buy Versanis Bio for up to $1.925 billion...

July 14, 2023, 1:51 pm

Eli lilly to acquire obesity drug maker versanis for $1.9 billion

The deal is Eli Lilly's latest attempt to capitalize on the weight loss industry gold rush, which was sparked by demand for Novo Nordisk's Wegovy and ...

July 14, 2023, 11:20 am

Eli lilly spends up to $1.93b to acquire obesity drug developer versanis

Eli Lilly and Co (NYSE:LLY) announced on Friday that it will buy privately held drug developer Versanis for up to $1.93 billion, in a bid to improve ...

July 14, 2023, 9:56 am

Eli lilly to acquire versanis bio, maker of obesity treatment

Versanis shareholders could receive as much as $1.925 billion in cash, which will consist of an upfront payment and additional payments if certain mil...

July 14, 2023, 8:55 am

Lilly to buy versanis for up to $1.93 bln to boost obesity drug portfolio

Eli Lilly and Co said on Friday it will acquire privately held drug developer Versanis for up to $1.93 billion, in a bid to boost its portfolio of ...

July 14, 2023, 8:14 am

Eli lilly to acquire versanis bio, expanding obesity-treatment pipeline

Eli Lilly and Co. LLY, -1.34% will acquire Versanis Bio, a private clinical-stage biopharma company focused on new treatments for cardiometabolic dise...

July 14, 2023, 8:14 am

The blazing weight-loss drug battle: can anyone unseat undisputed leaders novo nordisk and lilly?

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For ...

July 13, 2023, 1:37 pm

Novo nordisk (nvo) falls on ema safety review of obesity drugs

Novo Nordisk's (NVO) important diabetes care and obesity drugs are under review by the EMA's safety com...

July 12, 2023, 9:34 am


Search within

Pages Search Results: